Muneesh Tewari

Career Trajectory

Research Cluster Map

Direct collaborators. Node size = influence, colour = community, dashed = past collaboration.

• Validation of MyHPVscore

  Journal of Molecular Diagnostics · 2026-05-04

• A digital biomarker dataset from hematopoietic cell transplant caregivers and patients

  Scientific Data · 2026-03-27

• Supplementary Figure 1 from FDG-PET–Based Selective Deescalation of Chemoradiation in Human Papillomavirus–Related Oropharyngeal Squamous Cell Carcinoma: A Multicenter Phase II Trial

  2026-02-17

• Supplementary Table 3 from FDG-PET–Based Selective Deescalation of Chemoradiation in Human Papillomavirus–Related Oropharyngeal Squamous Cell Carcinoma: A Multicenter Phase II Trial

  2026-02-17

• Supplementary Figure 5 from FDG-PET–Based Selective Deescalation of Chemoradiation in Human Papillomavirus–Related Oropharyngeal Squamous Cell Carcinoma: A Multicenter Phase II Trial

  2026-02-17

• Data from FDG-PET–Based Selective Deescalation of Chemoradiation in Human Papillomavirus–Related Oropharyngeal Squamous Cell Carcinoma: A Multicenter Phase II Trial

  2026-02-17

• Supplementary Table 6 from FDG-PET–Based Selective Deescalation of Chemoradiation in Human Papillomavirus–Related Oropharyngeal Squamous Cell Carcinoma: A Multicenter Phase II Trial

  2026-02-17

• Supplementary Table 2 from FDG-PET–Based Selective Deescalation of Chemoradiation in Human Papillomavirus–Related Oropharyngeal Squamous Cell Carcinoma: A Multicenter Phase II Trial

  2026-02-17

• Supplementary Figure 3 from FDG-PET–Based Selective Deescalation of Chemoradiation in Human Papillomavirus–Related Oropharyngeal Squamous Cell Carcinoma: A Multicenter Phase II Trial

  2026-02-17

• Supplementary Figure 2 from FDG-PET–Based Selective Deescalation of Chemoradiation in Human Papillomavirus–Related Oropharyngeal Squamous Cell Carcinoma: A Multicenter Phase II Trial

  2026-02-17

• Supplementary Table 4 from FDG-PET–Based Selective Deescalation of Chemoradiation in Human Papillomavirus–Related Oropharyngeal Squamous Cell Carcinoma: A Multicenter Phase II Trial

  2026-02-17

• Supplementary Figure 4 from FDG-PET–Based Selective Deescalation of Chemoradiation in Human Papillomavirus–Related Oropharyngeal Squamous Cell Carcinoma: A Multicenter Phase II Trial

  2026-02-17

• Supplementary Data 1 from FDG-PET–Based Selective Deescalation of Chemoradiation in Human Papillomavirus–Related Oropharyngeal Squamous Cell Carcinoma: A Multicenter Phase II Trial

  2026-02-17

• Supplementary Table 5 from FDG-PET–Based Selective Deescalation of Chemoradiation in Human Papillomavirus–Related Oropharyngeal Squamous Cell Carcinoma: A Multicenter Phase II Trial

  2026-02-17

• Supplementary Table 1 from FDG-PET–Based Selective Deescalation of Chemoradiation in Human Papillomavirus–Related Oropharyngeal Squamous Cell Carcinoma: A Multicenter Phase II Trial

  2026-02-17

• FDG-PET–Based Selective Deescalation of Chemoradiation in Human Papillomavirus–Related Oropharyngeal Squamous Cell Carcinoma: A Multicenter Phase II Trial

  Clinical Cancer Research · 2025-12-12 · 3 citations

• Machine learning analysis of continuous body temperature data to differentiate between infectious and non-infectious fevers in bone marrow transplant recipients.

  JCO Oncology Practice · 2025-10-01

• HPV ctDNA Kinetics during Radiation and in Surveillance in a Phase II De-Escalation Trial for Early-Stage p16+ Oropharynx Cancer

  International Journal of Radiation Oncology*Biology*Physics · 2025-09-01

• Chromato-Kinetic Fingerprinting Enables Multiomic Digital Counting of Single Disease Biomarker Molecules

  ACS Nano · 2025-06-13 · 3 citations

• Pilot study of intestinal microbiome alteration with resistant potato starch (RPS) in patients (pts) treated with dual immune checkpoint inhibitors (ICI).

  Journal of Clinical Oncology · 2025-05-28